The developed world has long forced American patients to disproportionately shoulder the cost of pharmaceutical innovation. And President Donald Trump has had enough. He recently put our allies on notice—by launching a formal trade investigation into Germany’s unfair drug pricing practices and signaling his readiness to formally investigate other nations if they refuse to change course.
Those investigations are desperately needed. Germany’s government is poised to enact an even more aggressive price-setting scheme in the coming weeks, and Japan’s leaders are considering similar steps.